☆ 4.6 Article

Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma

JAMA ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Urology & Nephrology

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Matthew S. Ernst et al.

Summary: This study establishes real-world clinical benchmarks for immune-oncology (IO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combination treatments in metastatic renal cell carcinoma (mRCC) patients, based on the International mRCC Database Consortium (IMDC) criteria.

EUROPEAN UROLOGY (2023)

Add to Collection

Article Oncology

Deciphering radiological stable disease to immune checkpoint inhibitors

J. Luo et al.

Summary: Stable disease (SD) defined in immunotherapy is common and diverse, mainly reflecting tumor growth rate rather than response to immune checkpoint inhibitors. When the progression-free survival (PFS) of stable disease patients with no tumor growth exceeds 6 months, they can be considered as "SD responders". This definition improves the efficiency and insight of clinical and translational research.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial

U. T. Hacker et al.

Summary: In this study, the researchers investigated the role of the modified Glasgow prognostic score (mGPS) in predicting sarcopenia and body composition parameters and its prognostic role in conjunction with these parameters. They found that mGPS was strongly prognostic for overall survival (OS) but did not predict a decline in muscle or adipose tissue parameters. Eastern Cooperative Oncology Group performance status with CRP or mGPS remained the only baseline prognostic factors for OS.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers-ready for prime time?

S. Arulananda et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer cachexia: a nutritional or a systemic inflammatory syndrome?

Josh McGovern et al.

Summary: Cancer cachexia has traditionally been viewed as a nutritional syndrome, but recent research suggests that it may be primarily a manifestation of systemic inflammation. This has important implications for future treatment strategies.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma

Niklas Kluemper et al.

Summary: The study finds that early C-reactive protein (CRP) kinetics can serve as biomarkers to predict immunotherapy response and outcomes in patients with metastatic urothelial carcinoma (mUC). Particularly, CRP flare responders show more favorable treatment outcomes.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Niklas Kluemper et al.

Summary: Early dynamics of C reactive protein (CRP) can serve as a predictive biomarker for response to anti-PD-1 immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC). CRP flare-responders can predict ICB response and survival as early as 4 weeks after therapy initiation. Early CRP kinetics have no predictive value for chemoimmunotherapy or when steroids are administered concurrently.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Letter Oncology

In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score

J. Saal et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Y. Tomita et al.

Summary: This study examines the association between C-reactive protein (CRP) levels and the efficacy of treatment for renal cell carcinoma. The findings suggest that changes in CRP levels may predict the effectiveness of avelumab plus axitinib therapy.

ESMO OPEN (2022)

Add to Collection

Editorial Material Urology & Nephrology

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care

Jens Bedke et al.

Summary: The recent trials have shown improved survival benefits with immune checkpoint inhibitor combinations in advanced kidney cancer, particularly with lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatments for advanced kidney cancer.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Thomas Powles et al.

Summary: The IMmotion150 study assessed the efficacy and safety of atezolizumab + bevacizumab as second-line treatment for metastatic clear cell renal cancer patients who had disease progression on atezolizumab or sunitinib monotherapy. The results indicated that this combination therapy showed activity and tolerability in some patients, but limitations included a small sample size and selection bias for progressors.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

Shohei Fukuda et al.

Summary: The study found that the CRP flare-response group among mRCC patients was associated with significant tumor shrinkage and improved survival outcomes compared to the other two groups. Early CRP kinetics may be useful for evaluating the efficacy of nivolumab treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Nutrition & Dietetics

Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care

Geisiane Alves da Silva et al.

CLINICAL NUTRITION (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini et al.

LANCET (2019)

Add to Collection

Article Multidisciplinary Sciences

The prevalence of deranged C-reactive protein and albumin in patients with incurable cancer approaching death

Sarah Gray et al.

PLOS ONE (2018)

Add to Collection

Article Oncology

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

M. J. Proctor et al.

BRITISH JOURNAL OF CANCER (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.